SMTA2 NEGOTIATING STRATEGY AND ACHIEVEMENTS

Through the 13 SMTA2s signed to date, WHO has secured approximately 420 million doses of pandemic vaccine that it will be able to send to countries in need at the time of the next pandemic. This represents four times the amount of vaccine the Organization had access to during the 2009 pandemic. In addition, WHO will have access to 10 million treatment courses of antivirals.

This milestone was achieved through WHO’s strategic approach to focus on concluding agreements with the largest influenza vaccine manufacturers first. These manufacturers were targeted not only for their size but also because they have export experience and prequalified products, so when pandemic vaccine production begins, they will be able to supply vaccine the most rapidly to WHO. All vaccines and other pandemic products must be prequalified in order to be supplied to a UN agency such as WHO.

More information about the WHO Prequalification Program:
http://www.who.int/mediacentre/factsheets/fs278/en/

This strategy has been successful, and to date WHO has concluded an SMTA2 with all of the large multinational companies, which includes 6 of the 7 companies with a prequalified influenza vaccine.

NEXT STEPS
WHO will continue to conclude SMTA2s with all remaining influenza vaccine manufacturers.
## Commitments to date

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>COMMITMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vaccine donation*</td>
</tr>
<tr>
<td>China National Biotech Group</td>
<td>8%</td>
</tr>
<tr>
<td>Denka Seiken</td>
<td>8%</td>
</tr>
<tr>
<td>Glaxo Group Limited</td>
<td>7.5%</td>
</tr>
<tr>
<td>Green Cross Corporation</td>
<td>7%</td>
</tr>
<tr>
<td>Kitasato Daiichi Sankyo Limited</td>
<td>8%</td>
</tr>
<tr>
<td>KM Biologics Co., Ltd.</td>
<td>8%</td>
</tr>
<tr>
<td>MedImmune LLC</td>
<td>9%</td>
</tr>
<tr>
<td>The Research Foundation for Microbial Diseases of Osaka University (BIKEN)</td>
<td>8%</td>
</tr>
<tr>
<td>Sanofi Pasteur</td>
<td>7.5%</td>
</tr>
<tr>
<td>Seqirus UK Limited</td>
<td>10%</td>
</tr>
<tr>
<td>Serum Institute of India</td>
<td>8%</td>
</tr>
<tr>
<td>Sinovac Biotech Co</td>
<td>8%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Company Limited</td>
<td>8%</td>
</tr>
</tbody>
</table>

* Percentage of real-time pandemic vaccine production

Updated as of: May 2019